Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW)

$123.91 2.19 (1.80 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$123.91
Today's Range$121.86 - $124.10
52-Week Range$86.55 - $124.10
Volume1.26 million shs
Average Volume1.33 million shs
Market Capitalization$26.22 billion
P/E Ratio36.02
Dividend YieldN/A
Beta0.51

About Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences logoEdwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSE:EW
CUSIP28176E10
Phone+1-949-2502500

Debt

Debt-to-Equity Ratio0.33%
Current Ratio3.49%
Quick Ratio2.76%

Price-To-Earnings

Trailing P/E Ratio36.0203488372093
Forward P/E Ratio32.95
P/E Growth1.93

Sales & Book Value

Annual Sales$2.96 billion
Price / Sales8.85
Cash Flow$3.33 per share
Price / Cash37.22
Book Value$12.09 per share
Price / Book10.25

Profitability

Trailing EPS$3.44
Net Income$569.50 million
Net Margins20.71%
Return on Equity22.36%
Return on Assets12.84%

Miscellaneous

Employees11,100
Outstanding Shares211,620,000

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Shares of Edwards Lifesciences split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences declared that its Board of Directors has approved a share buyback program on Thursday, December 7th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its shares are undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings results on Tuesday, October, 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts' consensus estimates of $0.86 by $0.02. The medical research company earned $821.50 million during the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences had a return on equity of 22.36% and a net margin of 20.71%. The business's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.68 EPS. View Edwards Lifesciences' Earnings History.

When will Edwards Lifesciences make its next earnings announcement?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY18 earnings guidance on Thursday, December, 7th. The company provided EPS guidance of $4.10-4.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.15. The company issued revenue guidance of $3.5-3.9 billion, compared to the consensus revenue estimate of $3.71 billion.Edwards Lifesciences also updated its FY17 guidance to $3.65-3.85 EPS.

Where is Edwards Lifesciences' stock going? Where will Edwards Lifesciences' stock price be in 2018?

19 brokers have issued twelve-month price targets for Edwards Lifesciences' stock. Their forecasts range from $105.00 to $150.00. On average, they anticipate Edwards Lifesciences' stock price to reach $129.87 in the next twelve months. View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:

  • 1. According to Zacks Investment Research, "Over the last six months, Edwards Lifesciences has outperformed the broader industry. Edwards Lifesciences’ second-quarter 2017 performance was quite promising . Moreover, the raised guidance for 2017 hints at brighter prospects. In fact, the guidance raise was backed by a strong performance by all of the company’s three product lines.   We believe that the recent FDA approvals for several products including SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting investors’ confidence on the stock. However, higher operating expenses raise concerns. The stock’s valuation is also stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (9/26/2017)
  • 2. Cowen Inc analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
  • 3. Evercore ISI analysts commented, "With lowered investor expectations, we believe EW shares are poised for a 'catch-up' trade and offers asymmetric risk-reward at current levels. As a result, we are upgrading shares to a Buy, and raising our PT to $110, which offers ~15% upside from current levels." (3/27/2017)

Who are some of Edwards Lifesciences' key competitors?

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:

  • Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
  • Scott B. Ullem, Chief Financial Officer, Corporate Vice President
  • Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
  • Catherine M. Szyman, Corporate Vice President- Critical Care
  • Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
  • Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
  • Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
  • Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
  • Kieran T. Gallahue, Independent Director
  • Leslie Stone Heisz, Independent Director

Who owns Edwards Lifesciences stock?

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.36%), Schwab Charles Investment Management Inc. (0.34%), Bank of Montreal Can (0.11%), National Pension Service (0.10%), Factory Mutual Insurance Co. (0.10%) and Vontobel Asset Management Inc. (0.09%). Company insiders that own Edwards Lifesciences stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences.

Who sold Edwards Lifesciences stock? Who is selling Edwards Lifesciences stock?

Edwards Lifesciences' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Chesley Taft & Associates LLC, Westpac Banking Corp, First Citizens Bank & Trust Co., Exxonmobil Investment Management Inc. TX, Nisa Investment Advisors LLC, Oakbrook Investments LLC and Wealth Enhancement Advisory Services LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Larry L Wood, Michael A Mussallem, Patrick B Verguet and Schack Wesley W Von. View Insider Buying and Selling for Edwards Lifesciences.

Who bought Edwards Lifesciences stock? Who is buying Edwards Lifesciences stock?

Edwards Lifesciences' stock was bought by a variety of institutional investors in the last quarter, including Vontobel Asset Management Inc., Bank of Montreal Can, Country Trust Bank, Schwab Charles Investment Management Inc., Factory Mutual Insurance Co., State of Alaska Department of Revenue, First National Trust Co and Bath Savings Trust Co. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy Edwards Lifesciences stock?

Shares of Edwards Lifesciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of Edwards Lifesciences stock can currently be purchased for approximately $123.91.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $26.22 billion and generates $2.96 billion in revenue each year. The medical research company earns $569.50 million in net income (profit) each year or $3.44 on an earnings per share basis. Edwards Lifesciences employs 11,100 workers across the globe.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is 1 Edwards Way, IRVINE, CA 92614-5688, United States. The medical research company can be reached via phone at +1-949-2502500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  822 (Vote Outperform)
Underperform Votes:  588 (Vote Underperform)
Total Votes:  1,410
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Edwards Lifesciences (NYSE:EW) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.842.842.802.73
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $129.87$126.31$120.05$114.95
Price Target Upside: 13.33% upside7.02% upside8.67% upside1.68% downside

Edwards Lifesciences (NYSE:EW) Consensus Price Target History

Price Target History for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE:EW) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018BarclaysUpgradeEqual Weight -> Overweight$125.00 -> $135.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$140.00HighView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeOverweight -> NeutralMediumView Rating Details
12/10/2017CowenSet Price TargetBuy$135.00LowView Rating Details
12/8/2017BMO Capital MarketsReiterated RatingBuy$137.00LowView Rating Details
11/29/2017Canaccord GenuityReiterated RatingBuy$137.00LowView Rating Details
10/26/2017Deutsche BankLower Price TargetHold$122.00 -> $115.00N/AView Rating Details
10/26/2017Morgan StanleyLower Price TargetOverweight$133.00 -> $120.00N/AView Rating Details
10/25/2017SunTrust BanksSet Price TargetBuy$124.00N/AView Rating Details
9/1/2017Royal Bank of CanadaReiterated RatingBuy$130.00N/AView Rating Details
8/28/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
7/27/2017Stifel NicolausReiterated RatingBuy -> Buy$118.00 -> $130.00HighView Rating Details
7/27/2017Bank of AmericaBoost Price TargetPositive -> Buy$140.00 -> $150.00HighView Rating Details
7/27/2017Jefferies GroupBoost Price TargetBuy$115.00 -> $132.00HighView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageConviction-Buy$138.00LowView Rating Details
3/20/2017Northland SecuritiesSet Price TargetBuy$105.00LowView Rating Details
2/8/2017Credit Suisse GroupSet Price TargetBuy$120.00N/AView Rating Details
2/2/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
1/3/2017GuggenheimUpgradeNeutral -> Buy$120.00N/AView Rating Details
12/10/2016JMP SecuritiesReiterated RatingEqual Weight$130.00N/AView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
7/27/2016CitigroupBoost Price TargetSell$86.00 -> $94.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$123.00N/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$101.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Edwards Lifesciences (NYSE:EW) Earnings History and Estimates Chart

Earnings by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$0.90N/AView Earnings Details
10/24/2017Q3 2017$0.86$0.84$833.85 million$821.50 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.88$1.08$839.16 million$842.00 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.82$0.94$776.51 million$883.50 millionViewN/AView Earnings Details
2/1/2017Q416$0.72$0.75$760.85 million$767.70 millionViewN/AView Earnings Details
10/25/2016Q316$0.68$0.68$749.14 million$739.40 millionViewN/AView Earnings Details
7/26/2016Q216$0.70$0.76$724.26 million$759.30 millionViewN/AView Earnings Details
4/26/2016Q116$0.66$0.71$664.53 million$697.30 millionViewN/AView Earnings Details
2/2/2016Q415$0.62$0.63$647.44 million$671.10 millionViewN/AView Earnings Details
10/26/2015Q315$0.98$1.07$598.29 million$615.00 millionViewN/AView Earnings Details
7/28/2015Q215$1.05$1.13$604.97 million$616.80 millionViewN/AView Earnings Details
4/23/2015Q115$1.04$1.12$585.16 million$590.30 millionViewN/AView Earnings Details
2/3/2015Q414$0.95$1.06$610.50 million$618.00 millionViewListenView Earnings Details
10/23/2014Q314$0.72$0.80$546.10 million$607.40 millionViewListenView Earnings Details
7/29/2014Q214$0.77$0.88$545.10 million$547.00 millionViewListenView Earnings Details
4/24/2014Q114$0.69$0.76$523.10 million$522.40 millionViewListenView Earnings Details
2/3/2014Q413$0.82$0.91$533.82 million$536.00 millionViewN/AView Earnings Details
10/28/2013Q313$0.66$0.68$490.96 million$496.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013$0.76$0.82$514.59 million$517.20 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.76$0.72$518.69 million$496.70 millionViewN/AView Earnings Details
2/4/2013Q4 2012$0.77$0.77$499.46 million$510.50 millionViewN/AView Earnings Details
10/19/2012$0.56$0.58ViewN/AView Earnings Details
7/24/2012$0.66$0.67ViewN/AView Earnings Details
4/24/2012Q1 2012$0.24$0.27ViewN/AView Earnings Details
2/2/2012$0.59$0.62ViewN/AView Earnings Details
10/19/2011$0.39$0.38ViewN/AView Earnings Details
7/21/2011$0.50$0.49ViewN/AView Earnings Details
4/20/2011$0.42$0.51ViewN/AView Earnings Details
2/2/2011$0.53$0.55ViewN/AView Earnings Details
10/25/2010Q3 2010$0.21$0.21ViewN/AView Earnings Details
7/21/2010Q2 2010$0.22$0.23ViewN/AView Earnings Details
4/20/2010Q1 2010$0.20$0.20ViewN/AView Earnings Details
2/4/2010Q4 2009$0.21$0.21ViewN/AView Earnings Details
10/21/2009Q3 2009$0.18$0.18ViewN/AView Earnings Details
7/20/2009Q2 2009$0.19$0.20ViewN/AView Earnings Details
4/27/2009Q1 2009$0.17$0.18ViewN/AView Earnings Details
2/3/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/21/2008Q3 2008$0.14$0.14ViewN/AView Earnings Details
7/22/2008Q2 2008$0.16$0.16ViewN/AView Earnings Details
4/22/2008Q1 2008$0.12$0.14ViewN/AView Earnings Details
2/5/2008Q4 2007$0.13$0.14ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Edwards Lifesciences (NYSE:EW) Earnings Estimates

2018 EPS Consensus Estimate: $4.16
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.98$1.09$1.02
Q2 20184$1.06$1.13$1.10
Q3 20184$0.93$1.03$0.99
Q4 20184$0.97$1.09$1.05
Q1 20191$1.11$1.11$1.11
Q2 20191$1.23$1.23$1.23
Q3 20191$1.14$1.14$1.14
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Edwards Lifesciences (NYSE:EW)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Edwards Lifesciences (NYSE EW) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 81.61%
Insider Trades by Quarter for Edwards Lifesciences (NYSE:EW)
Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/28/2018Donald E. Bobo, Jr.VPSell5,300$114.08$604,624.00View SEC Filing  
1/16/2018Larry L WoodVPSell6,300$121.00$762,300.00116,148View SEC Filing  
1/4/2018Michael A. MussallemCEOSell32,800$114.97$3,771,016.00View SEC Filing  
12/28/2017Donald E. Bobo, Jr.VPSell5,300$114.08$604,624.00View SEC Filing  
12/19/2017Michael A. MussallemCEOSell32,800$114.82$3,766,096.00View SEC Filing  
12/15/2017Larry L. WoodVPSell18,960$114.58$2,172,436.80View SEC Filing  
11/29/2017Donald E. Bobo, Jr.VPSell5,300$116.45$617,185.00View SEC Filing  
11/20/2017Michael A. MussallemCEOSell32,900$106.86$3,515,694.00View SEC Filing  
11/15/2017Larry L. WoodVPSell18,960$104.76$1,986,249.60View SEC Filing  
11/9/2017Schack Wesley W VonDirectorSell1,000$104.15$104,150.002,622View SEC Filing  
10/30/2017Donald E. Bobo, Jr.VPSell5,300$101.12$535,936.00View SEC Filing  
10/30/2017Michael A. MussallemCEOSell32,900$100.93$3,320,597.00View SEC Filing  
10/16/2017Larry L WoodVPSell18,960$108.54$2,057,918.40View SEC Filing  
9/29/2017Donald E. Bobo, Jr.VPSell5,300$108.86$576,958.00View SEC Filing  
9/15/2017Larry L. WoodVPSell18,960$112.58$2,134,516.80View SEC Filing  
9/7/2017Michael A. MussallemCEOSell32,900$112.45$3,699,605.00View SEC Filing  
8/30/2017Larry L. WoodVPSell18,960$111.81$2,119,917.60View SEC Filing  
8/29/2017Donald E. Bobo, Jr.VPSell5,300$112.15$594,395.00View SEC Filing  
8/9/2017Michael A. MussallemCEOSell32,900$115.99$3,816,071.00View SEC Filing  
8/4/2017Donald E. Bobo, Jr.VPSell25,000$116.00$2,900,000.00View SEC Filing  
7/31/2017Catherine M. SzymanVPSell4,681$115.78$541,966.18View SEC Filing  
7/31/2017Michael A. MussallemCEOSell32,900$114.80$3,776,920.00View SEC Filing  
7/28/2017Donald E. Bobo, Jr.VPSell5,300$114.68$607,804.00View SEC Filing  
6/29/2017Donald E. Bobo, Jr.VPSell5,600$117.15$656,040.00View SEC Filing  
6/7/2017Michael A. MussallemCEOSell32,900$118.05$3,883,845.00View SEC Filing  
5/31/2017Patrick B. VerguetVPSell10,000$114.88$1,148,800.00View SEC Filing  
5/19/2017Dylan SidooDirectorBuy25,000$0.11$2,750.00
5/19/2017Patrick B. VerguetVPSell22,631$113.16$2,560,923.96View SEC Filing  
5/15/2017Patrick B. VerguetVPSell11,500$111.64$1,283,860.00View SEC Filing  
5/8/2017Donald E. Bobo, Jr.VPSell19,100$110.34$2,107,494.00View SEC Filing  
5/4/2017Donald E. Bobo, Jr.VPSell34,120$109.98$3,752,517.60View SEC Filing  
5/3/2017Michael A. MussallemCEOSell49,100$109.71$5,386,761.00View SEC Filing  
4/28/2017Michael A. MussallemCEOSell49,100$109.78$5,390,198.00View SEC Filing  
4/27/2017Bernard J. ZovighianVPSell18,050$109.21$1,971,240.50View SEC Filing  
4/5/2017Donald E. Bobo, Jr.VPSell13,720$93.58$1,283,917.60View SEC Filing  
3/30/2017Patrick B. VerguetVPSell24,000$93.90$2,253,600.00View SEC Filing  
3/6/2017Donald E. Bobo, Jr.VPSell13,720$90.01$1,234,937.20View SEC Filing  
2/16/2017Michael A. MussallemCEOSell49,100$89.63$4,400,833.00View SEC Filing  
2/3/2017Kieran GallahueDirectorBuy3,000$90.10$270,300.002,524View SEC Filing  
1/13/2017Michael A. MussallemCEOSell49,100$97.08$4,766,628.00View SEC Filing  
1/12/2017Donald E. Bobo, Jr.VPSell13,720$97.47$1,337,288.40View SEC Filing  
1/12/2017Dylan SidooDirectorBuy30,000$0.13$3,900.00
1/11/2017Dylan SidooDirectorBuy20,000$0.13$2,600.00
12/19/2016Michael A. MussallemCEOSell49,100$91.96$4,515,236.00View SEC Filing  
12/5/2016Huimin WangVPSell13,650$83.53$1,140,184.50View SEC Filing  
12/1/2016Larry L. WoodVPSell13,258$81.85$1,085,167.30View SEC Filing  
11/30/2016Catherine M. SzymanVPBuy12,870$83.43$1,073,744.10View SEC Filing  
11/29/2016Kieran GallahueDirectorBuy3,000$84.63$253,890.00View SEC Filing  
11/22/2016Michael A. MussallemCEOSell49,100$84.67$4,157,297.00View SEC Filing  
11/7/2016Huimin WangVPSell13,650$91.29$1,246,108.50View SEC Filing  
11/2/2016Donald E. Bobo, Jr.VPSell15,000$90.13$1,351,950.00View SEC Filing  
11/1/2016Larry L. WoodVPSell13,257$93.27$1,236,480.39View SEC Filing  
10/27/2016Michael A. MussallemCEOSell49,100$92.77$4,555,007.00View SEC Filing  
10/5/2016Huimin WangVPSell13,650$120.04$1,638,546.00View SEC Filing  
10/3/2016Larry L. WoodVPSell13,257$119.27$1,581,162.39View SEC Filing  
9/6/2016Huimin WangVPSell13,650$115.72$1,579,578.00View SEC Filing  
9/2/2016Donald E. Bobo, Jr.VPSell18,000$115.78$2,084,040.00View SEC Filing  
8/26/2016Patrick B. VerguetVPSell5,000$114.88$574,400.00View SEC Filing  
8/24/2016Patrick B. VerguetVPSell5,000$116.81$584,050.00View SEC Filing  
8/23/2016Patrick B. VerguetVPSell10,092$117.53$1,186,112.76View SEC Filing  
8/11/2016Michael A. MussallemCEOSell49,100$114.01$5,597,891.00View SEC Filing  
8/10/2016John T. CardisDirectorSell5,000$113.21$566,050.00View SEC Filing  
8/9/2016Patrick B. VerguetVPSell10,000$113.48$1,134,800.00View SEC Filing  
8/5/2016Huimin WangVPSell13,650$113.03$1,542,859.50View SEC Filing  
8/1/2016Larry L. WoodVPSell13,257$114.24$1,514,479.68View SEC Filing  
8/1/2016Schack Wesley W. VonDirectorSell6,000$113.98$683,880.00View SEC Filing  
7/29/2016Robert W.A. SellersVPSell10,000$114.33$1,143,300.00View SEC Filing  
7/28/2016Michael A. MussallemCEOSell49,100$113.31$5,563,521.00View SEC Filing  
7/5/2016Huimin WangVPSell13,650$98.44$1,343,706.00View SEC Filing  
7/1/2016Larry L. WoodVPSell13,257$98.79$1,309,659.03View SEC Filing  
6/8/2016Michael A MussallemCEOSell49,100$102.75$5,045,025.00127,341View SEC Filing  
6/6/2016Huimin WangVPSell13,650$101.34$1,383,291.0089,272View SEC Filing  
6/3/2016Larry L WoodVPSell13,257$101.38$1,343,994.66115,083View SEC Filing  
5/31/2016Donald E Bobo JrVPSell18,000$99.04$1,782,720.0062,796View SEC Filing  
5/24/2016Steven R LorangerDirectorBuy5,000$101.07$505,350.001,941View SEC Filing  
5/18/2016Patrick B VerguetVPSell13,000$102.75$1,335,750.00129,944View SEC Filing  
5/17/2016Patrick B VerguetVPSell5,000$105.00$525,000.00129,944View SEC Filing  
5/16/2016Patrick B VerguetVPSell3,000$104.62$313,860.00129,944View SEC Filing  
5/5/2016Huimin WangVPSell13,650$103.36$1,410,864.0081,480View SEC Filing  
5/5/2016Michael A MussallemCEOSell59,000$104.12$6,143,080.0068,256View SEC Filing  
5/2/2016Patrick B VerguetVPSell7,000$106.86$748,020.00115,107View SEC Filing  
4/29/2016Michael A MussallemCEOSell59,000$106.13$6,261,670.0079,256View SEC Filing  
4/5/2016Huimin WangVPSell13,650$103.97$1,419,190.5081,480View SEC Filing  
3/17/2016Michael A MussallemCEOSell59,000$84.39$4,979,010.0080,650View SEC Filing  
3/7/2016Huimin WangVPSell13,650$87.17$1,189,870.5081,299View SEC Filing  
2/18/2016Michael A. MussallemCEOSell59,000$86.94$5,129,460.00View SEC Filing  
2/18/2016Patrick B. VerguetVPSell5,000$87.00$435,000.00View SEC Filing  
2/16/2016Patrick B. VerguetVPSell8,000$81.58$652,640.00View SEC Filing  
2/5/2016Huimin WangVPSell13,650$83.46$1,139,229.00View SEC Filing  
2/4/2016Barbara J. McneilDirectorSell4,000$83.29$333,160.00View SEC Filing  
1/21/2016Patrick B. VerguetVPSell8,000$77.00$616,000.0099,803View SEC Filing  
1/6/2016Nick DemareDirectorBuy15,000$0.08$1,200.00
1/5/2016Huimin WangVPSell13,650$78.50$1,071,525.0067,649View SEC Filing  
1/5/2016Michael A. MussallemCEOSell59,000$79.82$4,709,380.0021,650View SEC Filing  
12/17/2015Michael A. MussallemCEOSell59,000$81.85$4,829,150.0021,650View SEC Filing  
12/15/2015Patrick B. VerguetVPSell8,000$80.87$646,960.0099,803View SEC Filing  
12/4/2015Huimin WangVPSell6,880$157.96$1,086,764.8033,824View SEC Filing  
11/27/2015Patrick B. VerguetVPSell7,500$164.50$1,233,750.0049,901View SEC Filing  
11/23/2015Robert W.A. SellersVPSell19,200$157.13$3,016,896.0013,158View SEC Filing  
11/17/2015Patrick B. VerguetVPSell4,000$154.50$618,000.0049,901View SEC Filing  
11/5/2015Huimin WangVPSell6,920$156.01$1,079,589.2034,174View SEC Filing  
11/3/2015Patrick B. VerguetVPSell4,338$158.48$687,486.2449,901View SEC Filing  
10/30/2015Patrick B. VerguetVPSell22,000$155.09$3,411,980.0049,901View SEC Filing  
10/29/2015Michael A MussallemCEOSell29,500$154.59$4,560,405.0040,325View SEC Filing  
10/5/2015Huimin WangVPSell6,920$154.30$1,067,756.0034,174View SEC Filing  
10/2/2015Patrick B. VerguetVPSell4,000$154.00$616,000.0053,901View SEC Filing  
10/1/2015Larry L. WoodVPSell7,680$141.52$1,086,873.6043,838View SEC Filing  
9/21/2015Michael A. MussallemCEOSell29,500$142.49$4,203,455.0010,825View SEC Filing  
9/4/2015Huimin WangVPSell6,920$135.19$935,514.8034,174View SEC Filing  
9/1/2015Larry L. WoodVPSell7,680$137.50$1,056,000.0043,838View SEC Filing  
8/24/2015Michael A. MussallemCEOSell29,500$135.25$3,989,875.00279,887View SEC Filing  
8/13/2015West Petroleum Corp. EastInsiderBuy25,000$0.12$2,875.00
7/6/2015Huimin WangVPSell6,920$143.95$996,134.00View SEC Filing  
7/1/2015Larry L WoodVPSell7,680$143.51$1,102,156.80View SEC Filing  
6/24/2015Michael A MussallemCEOSell29,500$143.71$4,239,445.00View SEC Filing  
6/5/2015Huimin WangVPSell6,920$131.39$909,218.80View SEC Filing  
6/1/2015Larry L WoodVPSell7,680$130.47$1,002,009.60View SEC Filing  
5/29/2015Patrick B VerguetVPSell9,662$131.18$1,267,461.16View SEC Filing  
5/21/2015Barbara J McneilDirectorSell2,000$132.59$265,180.00View SEC Filing  
5/19/2015Robert Marc BustinDirectorSell10,000$0.18$1,750.00
5/1/2015Larry L WoodVPSell7,680$127.12$976,281.60View SEC Filing  
4/30/2015Michael A MussallemCEOSell29,500$128.99$3,805,205.00View SEC Filing  
4/6/2015Huimin WangVPSell6,920$140.24$970,460.80View SEC Filing  
4/1/2015Larry L WoodVPSell7,680$142.06$1,091,020.80View SEC Filing  
3/31/2015Robert Marc BustinDirectorBuy15,000$0.15$2,250.00
3/26/2015Michael A MussallemCEOSell29,500$140.10$4,132,950.00View SEC Filing  
3/2/2015Larry L WoodVPSell7,680$132.62$1,018,521.60View SEC Filing  
2/6/2015Huimin WangVPSell6,920$134.79$932,746.80View SEC Filing  
1/5/2015Huimin WangVPSell6,920$126.60$876,072.00View SEC Filing  
1/5/2015Michael A MussallemCEOSell29,500$128.20$3,781,900.00View SEC Filing  
12/22/2014Michael A MussallemCEOSell29,500$133.01$3,923,795.00View SEC Filing  
11/24/2014Michael A MussallemCEOSell29,500$124.25$3,665,375.00View SEC Filing  
11/13/2014Robert W.A. SellersVPSell3,400$124.27$422,518.00View SEC Filing  
11/10/2014Patrick B VerguetVPSell5,000$123.70$618,500.00View SEC Filing  
11/7/2014Schack Wesley W VonDirectorSell3,655$123.00$449,565.00View SEC Filing  
11/5/2014Huimin WangVPSell5,600$120.26$673,456.00View SEC Filing  
10/28/2014Barbara J McneilDirectorSell1,000$117.94$117,940.00View SEC Filing  
10/28/2014Michael A MussallemCEOSell29,500$117.06$3,453,270.00View SEC Filing  
10/28/2014Patrick B VerguetVPSell15,000$117.33$1,759,950.00View SEC Filing  
10/28/2014West Petroleum Corp. EastInsiderBuy15,000$0.12$1,800.00
10/27/2014Patrick B VerguetVPSell10,000$117.00$1,170,000.00View SEC Filing  
10/27/2014West Petroleum Corp. EastInsiderBuy20,000$0.13$2,600.00
10/24/2014Donald E Bobo JrVPSell30,000$114.25$3,427,500.00View SEC Filing  
10/24/2014West Petroleum Corp. EastInsiderBuy35,000$0.14$4,725.00
10/23/2014West Petroleum Corp. EastInsiderBuy40,000$0.15$5,800.00
10/6/2014Huimin WangVPSell5,600$107.00$599,200.00View SEC Filing  
10/3/2014Donald E Bobo JrVPSell25,000$105.00$2,625,000.00View SEC Filing  
9/29/2014Michael A MussallemCEOSell29,500$102.71$3,029,945.00View SEC Filing  
9/10/2014Donald E Bobo JrVPSell25,000$100.00$2,500,000.00View SEC Filing  
9/5/2014Huimin WangVPSell5,600$98.29$550,424.00View SEC Filing  
8/27/2014Carlyn D SolomonVPSell85,200$97.85$8,336,820.00View SEC Filing  
8/27/2014Michael A MussallemCEOSell29,500$98.14$2,895,130.00View SEC Filing  
8/18/2014John T CardisDirectorSell6,000$97.92$587,520.00View SEC Filing  
8/18/2014Larry L WoodVPSell63,752$97.85$6,238,133.20View SEC Filing  
8/13/2014Patrick B VerguetVPSell7,800$95.50$744,900.00View SEC Filing  
8/5/2014Patrick B VerguetVPSell15,000$94.05$1,410,750.00View SEC Filing  
8/4/2014Patrick B VerguetVPSell5,000$93.00$465,000.00View SEC Filing  
8/1/2014Patrick B VerguetVPSell5,000$92.00$460,000.00View SEC Filing  
7/31/2014Michael A MussallemCEOSell29,500$91.98$2,713,410.00View SEC Filing  
7/31/2014Robert Alexander IngramDirectorSell12,500$90.26$1,128,250.00View SEC Filing  
7/31/2014Robert W.A. SellersVPSell8,850$91.47$809,509.50View SEC Filing  
7/30/2014Donald E Bobo JrVPSell23,270$92.00$2,140,840.00View SEC Filing  
7/7/2014Huimin WangVPSell5,600$87.79$491,624.00View SEC Filing  
6/27/2014Donald E Bobo JrVPSell25,000$87.00$2,175,000.00View SEC Filing  
6/24/2014Michael A MussallemCEOSell29,500$85.38$2,518,710.00View SEC Filing  
6/5/2014Huimin WangVPSell5,600$80.73$452,088.00View SEC Filing  
5/30/2014Barbara J McneilDirectorSell1,200$81.20$97,440.00View SEC Filing  
5/28/2014Michael A MussallemCEOSell29,500$79.33$2,340,235.00View SEC Filing  
4/14/2014Donald Bobo, Jr.VPSell25,000$82.00$2,050,000.0020,604View SEC Filing  
4/10/2014Michael MussallemCEOSell29,500$74.71$2,203,945.00263,850View SEC Filing  
4/7/2014Huimin WangVPSell5,600$74.03$414,568.0031,549View SEC Filing  
3/24/2014Michael BowlinDirectorSell1,093$72.33$79,056.6977,199View SEC Filing  
3/6/2014Robert W.A. SellersVPSell1,650$72.88$120,252.0020,570View SEC Filing  
2/6/2014Michael MussallemCEOSell29,500$66.92$1,974,140.00263,850View SEC Filing  
1/27/2014Michael BowlinDirectorSell1,092$68.65$74,965.8077,199View SEC Filing  
1/9/2014Michael MussallemCEOSell29,500$67.04$1,977,680.00263,850View SEC Filing  
1/6/2014Huimin WangVPSell5,600$67.14$375,984.0031,337View SEC Filing  
12/11/2013Patrick VerguetVPSell10,000$62.34$623,400.0048,681View SEC Filing  
12/5/2013Huimin WangVPSell4,650$64.65$300,622.5031,337View SEC Filing  
12/4/2013Michael MussallemCEOSell29,500$64.90$1,914,550.00263,850View SEC Filing  
10/9/2013Michael MussallemCEOSell29,500$72.63$2,142,585.00263,850View SEC Filing  
10/4/2013Huimin WangVPSell4,850$72.19$350,121.5031,337View SEC Filing  
9/12/2013Michael MussallemCEOSell29,500$71.82$2,118,690.00263,850View SEC Filing  
9/5/2013Huimin WangVPSell4,850$71.24$345,514.0031,337View SEC Filing  
8/8/2013Michael MussallemCEOSell29,500$72.28$2,132,260.00263,850View SEC Filing  
8/5/2013Huimin WangVPSell4,850$72.30$350,655.0031,337View SEC Filing  
8/1/2013Patrick VerguetVPSell20,000$73.15$1,463,000.0048,681View SEC Filing  
7/10/2013Michael A MussallemCEOSell29,500$65.60$1,935,200.00View SEC Filing  
7/5/2013Huimin WangVPSell4,850$65.69$318,596.50View SEC Filing  
6/6/2013Michael A MussallemCEOSell29,500$66.25$1,954,375.00View SEC Filing  
6/5/2013Huimin WangVPSell4,850$65.11$315,783.50View SEC Filing  
5/13/2013Paul C RedmondVPSell5,000$67.35$336,750.00View SEC Filing  
5/8/2013Michael A MussallemCEOSell29,200$64.24$1,875,808.00View SEC Filing  
5/7/2013Thomas M AbateCFOSell15,000$63.75$956,250.00View SEC Filing  
5/3/2013Schack Wesley W VonDirectorBuy1,000$64.00$64,000.00View SEC Filing  
5/1/2013David E I PyottDirectorBuy3,000$62.95$188,850.00View SEC Filing  
5/1/2013John H Kehl JrVPSell12,500$62.72$784,000.00View SEC Filing  
4/26/2013Schack Wesley W VonDirectorBuy2,000$64.95$129,900.00View SEC Filing  
4/10/2013Michael A MussallemCEOSell35,000$83.37$2,917,950.00View SEC Filing  
3/13/2013John H Kehl JrVPSell12,500$87.75$1,096,875.00View SEC Filing  
10/5/2012Huimin WangVPSell6,250$109.88$686,750.00View SEC Filing  
10/4/2012Donald E Bobo JrVPSell11,530$110.14$1,269,914.20View SEC Filing  
8/9/2012Michael A MussallemCEOSell35,000$98.69$3,454,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Edwards Lifesciences (NYSE EW) News Headlines

Source:
DateHeadline
Comparing Edwards Lifesciences (EW) & IRIDEX (IRIX)Comparing Edwards Lifesciences (EW) & IRIDEX (IRIX)
www.americanbankingnews.com - January 19 at 9:35 PM
Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018
finance.yahoo.com - January 18 at 10:41 AM
Edwards Lifesciences Corp (EW) VP Sells $762,300.00 in StockEdwards Lifesciences Corp (EW) VP Sells $762,300.00 in Stock
www.americanbankingnews.com - January 17 at 9:32 PM
IBD Rating Upgrades: Edwards Lifesciences Shows Improved Relative Price StrengthIBD Rating Upgrades: Edwards Lifesciences Shows Improved Relative Price Strength
finance.yahoo.com - January 16 at 5:03 PM
Edwards Lifesciences Corporation -- Moodys upgrades Edwards Lifesciences to Baa2Edwards Lifesciences Corporation -- Moody's upgrades Edwards Lifesciences to Baa2
finance.yahoo.com - January 16 at 5:03 PM
Cramers lightning round: The analysts downgrading Edwards Lifesciences are knuckleheadsCramer's lightning round: The analysts downgrading Edwards Lifesciences are 'knuckleheads'
finance.yahoo.com - January 10 at 9:53 AM
Edwards Lifesciences Corp (EW) CEO Michael A. Mussallem Sells 32,800 SharesEdwards Lifesciences Corp (EW) CEO Michael A. Mussallem Sells 32,800 Shares
www.americanbankingnews.com - January 8 at 6:50 PM
Edwards Lifesciences Corp (EW) Given Consensus Rating of "Buy" by BrokeragesEdwards Lifesciences Corp (EW) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 5 at 7:40 PM
How Edwards Lifesciences’ Critical Care Business Is PositionedHow Edwards Lifesciences’ Critical Care Business Is Positioned
finance.yahoo.com - January 5 at 9:55 AM
Milestones Edwards Lifesciences Expects to Reach in 2018Milestones Edwards Lifesciences Expects to Reach in 2018
finance.yahoo.com - January 4 at 5:05 PM
Barclays Upgrades Edwards Lifesciences (EW) to Overweight - StreetInsider.comBarclays Upgrades Edwards Lifesciences (EW) to Overweight - StreetInsider.com
www.streetinsider.com - January 4 at 9:44 AM
Wall Street Analysts Upbeat on Edwards Lifesciences StockWall Street Analysts Upbeat on Edwards Lifesciences Stock
finance.yahoo.com - January 4 at 9:44 AM
How Edwards Lifesciences Expects to Continue Its Margin ExpansionHow Edwards Lifesciences Expects to Continue Its Margin Expansion
finance.yahoo.com - January 4 at 9:44 AM
What’s Expected to Drive Edwards Lifesciences’ 2018 EarningsWhat’s Expected to Drive Edwards Lifesciences’ 2018 Earnings
finance.yahoo.com - January 4 at 9:44 AM
EW’s Market Strategy for Its Surgical Heart Valve Therapy SegmentEW’s Market Strategy for Its Surgical Heart Valve Therapy Segment
finance.yahoo.com - January 3 at 5:08 PM
The Macro Environment and Edwards Lifesciences’ GrowthThe Macro Environment and Edwards Lifesciences’ Growth
finance.yahoo.com - January 3 at 5:08 PM
Why Jefferies Raised Its Target Price on EW StockWhy Jefferies Raised Its Target Price on EW Stock
finance.yahoo.com - January 3 at 5:08 PM
Discussing EW’s Surgical Heart Valve Therapies Product PipelineDiscussing EW’s Surgical Heart Valve Therapies Product Pipeline
finance.yahoo.com - January 3 at 5:08 PM
A Look at Edwards Lifesciences’ 2018 Sales GuidanceA Look at Edwards Lifesciences’ 2018 Sales Guidance
finance.yahoo.com - January 3 at 5:08 PM
Edwards Lifesciences’ New Therapies for Mitral and Tricuspid ValvesEdwards Lifesciences’ New Therapies for Mitral and Tricuspid Valves
finance.yahoo.com - January 3 at 9:03 AM
Edwards Lifesciences To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)Edwards Lifesciences To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 2 at 11:10 PM
Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare ConferenceEdwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 6:10 PM
Focused Innovation Strategy Leads Sustained Organic Sales Growth for EWFocused Innovation Strategy Leads Sustained Organic Sales Growth for EW
finance.yahoo.com - January 2 at 9:43 AM
Edwards Lifesciences (EW) Downgraded by JPMorgan Chase & Co.Edwards Lifesciences (EW) Downgraded by JPMorgan Chase & Co.
www.americanbankingnews.com - January 2 at 8:04 AM
Edwards Lifesciences Expands Portfolio with Harpoon Medical AcquisitionEdwards Lifesciences Expands Portfolio with Harpoon Medical Acquisition
finance.yahoo.com - January 1 at 9:43 AM
Recent Stock Price Performance of Edwards LifesciencesRecent Stock Price Performance of Edwards Lifesciences
finance.yahoo.com - January 1 at 9:43 AM
Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 5,300 Shares of StockInsider Selling: Edwards Lifesciences Corp (EW) VP Sells 5,300 Shares of Stock
www.americanbankingnews.com - January 1 at 4:26 AM
Edwards Lifesciences Corp (EW) Expected to Post Quarterly Sales of $862.69 MillionEdwards Lifesciences Corp (EW) Expected to Post Quarterly Sales of $862.69 Million
www.americanbankingnews.com - December 30 at 10:38 AM
Edwards Lifesciences Corp (EW) Short Interest Up 46.8% in NovemberEdwards Lifesciences Corp (EW) Short Interest Up 46.8% in November
www.americanbankingnews.com - December 19 at 3:26 AM
Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) StockLarry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock
www.americanbankingnews.com - December 15 at 8:52 PM
Kaman Corporation (KAMN) Ex-Dividend Date Scheduled for December 18, 2017 - NasdaqKaman Corporation (KAMN) Ex-Dividend Date Scheduled for December 18, 2017 - Nasdaq
www.nasdaq.com - December 15 at 10:16 AM
Zacks: Analysts Expect Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $862.69 MillionZacks: Analysts Expect Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $862.69 Million
www.americanbankingnews.com - December 13 at 11:36 AM
Edwards Lifesciences (EW) Ranking Raised to Buy on Robust Earnings GrowthEdwards Lifesciences (EW) Ranking Raised to Buy on Robust Earnings Growth
investorplace.com - December 12 at 12:35 PM
Edwards Lifesciences Corporation (EW) Given Average Rating of "Buy" by AnalystsEdwards Lifesciences Corporation (EW) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 10:22 PM
Edwards Lifesciences (EW) Given a $135.00 Price Target at CowenEdwards Lifesciences (EW) Given a $135.00 Price Target at Cowen
www.americanbankingnews.com - December 11 at 3:40 PM
Jefferies Group Research Analysts Boost Earnings Estimates for Edwards Lifesciences Corporation (EW)Jefferies Group Research Analysts Boost Earnings Estimates for Edwards Lifesciences Corporation (EW)
www.americanbankingnews.com - December 11 at 5:38 AM
Edwards Lifesciences Corporation to Post Q2 2018 Earnings of $1.12 Per Share, Leerink Swann Forecasts (EW)Edwards Lifesciences Corporation to Post Q2 2018 Earnings of $1.12 Per Share, Leerink Swann Forecasts (EW)
www.americanbankingnews.com - December 11 at 5:38 AM
Edwards Lifesciences Corporation to Post Q4 2017 Earnings of $0.89 Per Share, William Blair Forecasts (EW)Edwards Lifesciences Corporation to Post Q4 2017 Earnings of $0.89 Per Share, William Blair Forecasts (EW)
www.americanbankingnews.com - December 11 at 3:08 AM
BMO Capital Markets Reaffirms "Buy" Rating for Edwards Lifesciences (EW)BMO Capital Markets Reaffirms "Buy" Rating for Edwards Lifesciences (EW)
www.americanbankingnews.com - December 9 at 12:08 PM
Edwards Lifesciences (EW) to Acquire Harpoon Medical for $100M, Plus Up to $150M in Milestone PaymentsEdwards Lifesciences (EW) to Acquire Harpoon Medical for $100M, Plus Up to $150M in Milestone Payments
www.streetinsider.com - December 7 at 5:28 PM
Edwards Lifesciences Outlines Growth Strategy At Annual Investor ConferenceEdwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
finance.yahoo.com - December 7 at 5:28 PM
Edwards Lifesciences Board Approves New $1 Billion Share Repurchase ProgramEdwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program
finance.yahoo.com - December 7 at 5:28 PM
Edwards Lifesciences sets $1 billion stock buyback program, gives 2018 guidanceEdwards Lifesciences sets $1 billion stock buyback program, gives 2018 guidance
finance.yahoo.com - December 7 at 5:28 PM
[$$] Harpoon Medical Acquired by Edwards Lifesciences[$$] Harpoon Medical Acquired by Edwards Lifesciences
finance.yahoo.com - December 7 at 5:28 PM
Edwards Lifesciences (EW) Issues FY18 Earnings GuidanceEdwards Lifesciences (EW) Issues FY18 Earnings Guidance
www.americanbankingnews.com - December 7 at 5:08 PM
Edwards Lifesciences (EW) Releases FY17 Earnings GuidanceEdwards Lifesciences (EW) Releases FY17 Earnings Guidance
www.americanbankingnews.com - December 7 at 5:08 PM
Edwards Lifesciences (EW) to Repurchase $1.00 billion in   SharesEdwards Lifesciences (EW) to Repurchase $1.00 billion in Shares
www.americanbankingnews.com - December 7 at 11:26 AM
Edwards Lifesciences Board Approves New $1 Billion Share Repurchase Program - PR Newswire (press release)Edwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program - PR Newswire (press release)
www.prnewswire.com - December 7 at 10:04 AM
Edwards Lifesciences buys Harpoon Medical for $100M - Seeking AlphaEdwards Lifesciences buys Harpoon Medical for $100M - Seeking Alpha
seekingalpha.com - December 7 at 10:04 AM
Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards LifesciencesEpidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences
www.prnewswire.com - December 7 at 6:25 AM

SEC Filings

Edwards Lifesciences (NYSE:EW) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Edwards Lifesciences (NYSE:EW) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Edwards Lifesciences (NYSE EW) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.